FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL USING TRISPECIFIC (CD19/CD20/CD22) CAR T CELLS FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL LYMPHOMA

University Of Maryland, Baltimore

Investigators